Phase 2 Evidence and Impact Analysis
All 49 articles assessed below. Scores are my independent Phase 2 judgments; original triage_score is retained for transparency. All articles are abstract-only peer-reviewed publications; no preprints in this batch.
Article 1 — Zhang et al. — Iza-bren Phase 1b in advanced solid tumors (PMID: 42727637)
🟠 NOVEL_TREATMENT | Phase 1b clinical trial
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First-in-class bispecific ADC dual-targeting EGFR+HER3 simultaneously; addresses key mono-ADC resistance mechanism |
| Clinical Relevance | 7 | Phase 1b activity signal only; meaningful but premature for practice change |
| Population Reach | 7 | EGFR-mutated and WT solid tumors span multiple cancers; large addressable population |
| Implementation Speed | 3 | Phase 1b; years to approval if efficacy confirmed in pivotal trials |
| Evidence Strength | 5 | Phase 1b; no randomized comparison; sample size not reported |
Key quantitative result: Not specified in abstract; "meaningful antitumor activity" and "manageable safety" qualitative claims. External validation: None at this stage. Main limitation: Phase 1b single-arm; no comparative data; sample size undisclosed; abstract only. Equity: EGFR-mutated cancers more prevalent in East Asian women; global access to novel ADCs historically inequitable. Evidence Maturity (revised): Exploratory → early Phase 1b signal; "Potentially Practice-Changing" label is premature at this stage. Revised to Exploratory for current evidence. Original triage_score: 10
Article 2 — Zhang Y et al. — Cilta-cel cost-effectiveness in lenalidomide-refractory MM (CARTITUDE-4) (PMID: 42727844)
🟠 NOVEL_TREATMENT | Cost-effectiveness analysis (Phase III RCT data)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Cost-effectiveness analyses of approved agents are incrementally useful, not groundbreaking |
| Clinical Relevance | 9 | Directly informs payer coverage decisions; cilta-cel already FDA-approved but access restricted by cost |
| Population Reach | 6 | ~35,000 new MM diagnoses/year in US; relevant subgroup is lenalidomide-refractory |
| Implementation Speed | 7 | Findings immediately applicable to formulary/coverage debates; drug already approved |
| Evidence Strength | 7 | Built on Phase III CARTITUDE-4 RCT data; economic modeling assumptions are study-specific |
Key quantitative result: Cilta-cel cost-effective vs. SOC; specific ICER not reported in abstract. External validation: Based on CARTITUDE-4 Phase III RCT outcomes data — strong underlying evidence base. Main limitation: Model assumptions (discount rates, utility values, time horizon) heavily influence ICER; country-specific analysis limits global generalizability. Equity: CAR-T access is deeply inequitable — primarily available at academic centers; cost-effectiveness data could unlock broader reimbursement for underserved MM patients. Evidence Maturity (confirmed): Potentially Practice-Changing — for payer/coverage decisions specifically. Original triage_score: 9
Article 3 — Balic et al. — Tumor-informed ctDNA MRD in early TNBC (NeoAdjuvant setting) (PMID: 42727049)
🔴 EARLY_CANCER_DETECTION | Clinical validation study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Tumor-informed MRD in TNBC post-neoadjuvant is an active frontier; validates a specific assay design in well-characterized trial cohort |
| Clinical Relevance | 9 | TNBC has the highest recurrence risk and fewest adjuvant options; MRD could directly guide escalation/de-escalation |
| Population Reach | 7 | TNBC |
| Implementation Speed | 5 | Assay validated but prospective intervention trials needed before standard adoption |
| Evidence Strength | 7 | Clinical validation in trial cohort (likely large given author list and multi-center design); tumor-informed design is methodologically rigorous |
Key quantitative result: "Strongly associated with recurrence risk" — specific HR/sensitivity/specificity not reported in abstract. External validation: Embedded in adjuvant trial context (NSABP-linked given authors); multi-center validation inferred. Main limitation: Observational/correlative within trial; no randomized MRD-guided intervention arm yet; abstract only. Equity: TNBC disproportionately affects Black women and younger women; equitable access to ctDNA assays is a critical concern. Evidence Maturity (confirmed): Potentially Practice-Changing — strong prognostic validation; intervention RCTs needed. Original triage_score: 9
Article 4 — Ghasabi et al. — Systematic review of ML models for MCI-to-AD conversion prediction (PMID: 42727648)
🟢 NEAR_TERM_IMPLEMENTABLE | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ML for AD prediction is well-trodden territory; synthesis value but not groundbreaking |
| Clinical Relevance | 7 | AD has no disease-modifying treatment widely available; prediction value depends on intervention pipeline |
| Population Reach | 9 | ~55 million people with dementia globally; MCI population enormous |
| Implementation Speed | 4 | Clinical translation requires prospective validation, regulatory approval, and an actionable intervention |
| Evidence Strength | 6 | Systematic review quality; heterogeneous underlying studies; no primary data |
Key quantitative result: "High accuracy" — specific AUC/accuracy metrics not reported in abstract. External validation: Review of multiple models; individual studies not independently validated. Main limitation: Heterogeneity of input features, populations, and ML methods across included studies; publication bias risk; no intervention benefit demonstrated. Equity: Most validated models use imaging (MRI, PET) that is inaccessible in low/middle-income settings. Evidence Maturity (revised): Validated → more accurately Exploratory-to-Validated for prediction only; no proven clinical utility yet. Revised to Validated (prediction accuracy) with caveat that clinical benefit is unproven. Original triage_score: 9
Article 5 — Mironova et al. — Expert panel: resmetirom + semaglutide for MASH (PMID: 42728029)
🟠 NOVEL_TREATMENT | International expert panel review/consensus
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First expert consensus on first two FDA-approved MASH therapies; fills critical guidance gap |
| Clinical Relevance | 9 | Immediately actionable for hepatologists and primary care; drugs approved but no consensus guidance existed |
| Population Reach | 8 | MASH affects ~6.5M Americans, ~300M globally; rapidly rising prevalence |
| Implementation Speed | 8 | Expert guidance is directly and immediately usable by clinicians; no regulatory barrier |
| Evidence Strength | 5 | Expert consensus, not primary data; inherits strength of underlying RCTs (MAESTRO, ESSENCE) but consensus itself is opinion-based |
Key quantitative result: N/A (guidance document); underlying trials: resmetirom improved fibrosis in 25% of patients vs. 14% placebo.
External validation: Builds on FDA-approved trial data; consensus itself not independently validated.
Main limitation: Expert consensus carries inherent opinion bias; no head-to-head comparison between resmetirom and semaglutide; real-world effectiveness unknown.
Equity: MASH disproportionately affects Hispanic Americans and economically disadvantaged populations; drug cost ($50K+/year for resmetirom) is a major access barrier.
Evidence Maturity (confirmed): Potentially Practice-Changing — for clinical operationalization of already-approved therapies.
Original triage_score: 9
Article 6 — Thompson et al. — Evidence-based statin deprescribing guideline for adults ≥65 (PMID: 42728062)
🟢 NEAR_TERM_IMPLEMENTABLE | GRADE-based clinical practice guideline
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Deprescribing concept established; first GRADE-based statin-specific guideline for elderly is modestly novel |
| Clinical Relevance | 9 | Statins are most prescribed drug class in ≥65; directly actionable by any prescribing clinician |
| Population Reach | 9 | Tens of millions of adults ≥65 on statins globally |
| Implementation Speed | 8 | Guideline format designed for immediate clinical adoption; no infrastructure or regulatory barrier |
| Evidence Strength | 7 | GRADE methodology applied to systematic evidence review; gold standard for guideline development |
Key quantitative result: Not specified in abstract; GRADE recommendations provided. External validation: GRADE methodology incorporates external evidence; guideline itself not separately validated. Main limitation: Evidence base for deprescribing is sparser than for prescribing; recommendations likely conditional given limited RCT data on discontinuation outcomes. Equity: Older adults with frailty and polypharmacy are frequently underserved; guideline explicitly targets this population. Potential equity concern if deprescribing disproportionately reaches certain racial/ethnic groups without adequate monitoring. Evidence Maturity (confirmed): Potentially Practice-Changing — immediately applicable. Original triage_score: 9
Article 7 — Mulvey et al. — Molecular programs in locus coeruleus linking APOE and neuromelanin to AD vulnerability (PMID: 42726290)
⚪ PROMISING_PRELIMINARY | Single-cell transcriptomics (postmortem)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Spatially resolved single-cell transcriptomics of the LC with APOE-neuromelanin link is genuinely novel; LC is earliest-affected AD region |
| Clinical Relevance | 3 | Basic science discovery; no therapeutic application yet |
| Population Reach | 9 | AD affects 50M+ globally; any early vulnerability mechanism has massive reach potential |
| Implementation Speed | 1 | Pre-therapeutic; mechanism identification stage; 10+ year translation horizon |
| Evidence Strength | 5 | Human postmortem tissue; compelling molecular data but no functional validation or causality established |
Key quantitative result: Not reported in abstract. External validation: None yet; single study on postmortem tissue. Main limitation: Postmortem tissue; cannot establish causality; APOE-neuromelanin interaction mechanism not yet functionally tested in vivo. Equity: APOE4 genotype is more common in some populations; LC-first AD pathology may have different prevalence across ethnic groups. Evidence Maturity (confirmed): Exploratory. Original triage_score: 9
Article 8 — Narlı Özdemir et al. — FACIT-fatigue and treatment quality in PNH patients on eculizumab (PMID: 42726724)
🟡 UNDERSERVED_POPULATION | Multicenter observational study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Discordance between hematological and PRO response in PNH is clinically important but conceptually unsurprising |
| Clinical Relevance | 7 | Directly informs clinical monitoring protocols and future trial endpoint design in PNH |
| Population Reach | 3 | PNH is ultra-rare (~1–5/million); high relative unmet need |
| Implementation Speed | 7 | Findings immediately applicable to monitoring frameworks; no regulatory barrier |
| Evidence Strength | 6 | Multicenter (6 sites) observational; no comparator arm; limited by small absolute numbers |
Key quantitative result: Specific FACIT-fatigue score discordance magnitude not reported in abstract. External validation: Multi-center adds some external validity. Main limitation: Observational; PNH is heterogeneous; FACIT-fatigue instrument may not be adequately disease-specific. Equity: PNH patients in Turkey; data from a middle-income country setting — relevant for understanding treatment access in non-Western contexts. Evidence Maturity (confirmed): Validated (for PRO/hematological discordance finding). Original triage_score: 9
Article 9 — Briel et al. — Proteomic-guided targeted treatment of LCC (PMID: 42725622)
🟠 NOVEL_TREATMENT | Proof-of-concept translational study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First proteomics-guided precision treatment in LCC; novel methodological approach for ultra-rare neurological disease |
| Clinical Relevance | 4 | Single patient proof-of-concept; cannot generalize to population |
| Population Reach | 2 | LCC is extremely rare (estimated <200 known cases globally) |
| Implementation Speed | 3 | Proof-of-concept stage; needs broader validation |
| Evidence Strength | 3 | Single patient case; proof-of-concept only |
Key quantitative result: "Successful precision pharmacotherapy" — specifics not reported. External validation: None; single case. Main limitation: n=1; cannot assess efficacy or safety at population level; abstract only. Equity: Ultra-rare disease; patients often face diagnostic odyssey; proteomics approach is resource-intensive and not widely available. Evidence Maturity (confirmed): Exploratory. Original triage_score: 9 (appropriate given unmet need context; high relative to population size)
Article 10 — Hoyos et al. — Network meta-analysis: carotid endarterectomy vs. stenting vs. medical therapy (PMID: 42728198)
🟢 NEAR_TERM_IMPLEMENTABLE | Network meta-analysis of RCTs
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Ongoing controversy; updated NMA adds data but debate is not new |
| Clinical Relevance | 8 | Directly informs neurovascular and cardiovascular decisions for asymptomatic carotid stenosis |
| Population Reach | 8 | Carotid stenosis affects millions; asymptomatic stenosis is extremely common in aging populations |
| Implementation Speed | 6 | NMA findings can inform guidelines but requires professional society consensus to shift practice |
| Evidence Strength | 7 | Network meta-analysis of RCTs; appropriate methodology for comparative effectiveness |
Key quantitative result: Medical therapy non-inferior to revascularization in asymptomatic stenosis — specific NNT/event rates not reported in abstract. External validation: Synthesizes multiple RCTs; robust methodological framework. Main limitation: Network transitivity assumptions; heterogeneity in medical therapy definitions across included trials; asymptomatic vs. symptomatic stratification critical. Equity: Revascularization access highly variable by geography, hospital type, and insurance status; expanding role of medical therapy could equalize care. Evidence Maturity (confirmed): Validated. Original triage_score: 9
Article 11 — Planchard et al. — Long-term safety of osimertinib + platinum-pemetrexed (FLAURA2) (PMID: 42728193)
🟠 NOVEL_TREATMENT | Long-term safety follow-up from Phase III RCT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Confirmatory long-term safety data; not a new discovery |
| Clinical Relevance | 9 | Resolves the critical toxicity uncertainty that was the main barrier to broad FLAURA2 adoption |
| Population Reach | 8 | EGFR-mutated NSCLC is |
| Implementation Speed | 8 | Safety data can immediately shift practice; regimen already in use at leading centers |
| Evidence Strength | 8 | Phase III RCT long-term follow-up; gold standard study design |
Key quantitative result: "Manageable safety profile confirmed" — specific adverse event rates not reported in abstract. External validation: FLAURA2 is itself externally validated Phase III. Main limitation: Long-term safety still limited by follow-up duration; abstract only. Equity: EGFR mutations more prevalent in Asian and never-smoker populations; global access to osimertinib-combination therapy highly variable. Evidence Maturity (confirmed): Potentially Practice-Changing. Original triage_score: 9
Article 12 — Sturek et al. — Meta-analysis: ctDNA and recurrence in HPV+ oropharyngeal cancer (PMID: 42726930)
🔴 EARLY_CANCER_DETECTION | Systematic review and meta-analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ctDNA surveillance in HPV+ OPC is an active field; meta-analysis synthesizes existing evidence |
| Clinical Relevance | 8 | Directly supports protocol change from imaging-alone to ctDNA-augmented surveillance |
| Population Reach | 6 | HPV+ OPC incidence ~15,000/year US; rising globally |
| Implementation Speed | 6 | ctDNA assays available but not yet standard-of-care surveillance; protocol change needed |
| Evidence Strength | 6 | Meta-analysis of likely heterogeneous observational studies; HPV ctDNA (HPV-ctDNA) may differ methodologically |
Key quantitative result: "High sensitivity" — specific pooled sensitivity/specificity not reported in abstract. External validation: Pooled across multiple studies. Main limitation: HPV-ctDNA assay heterogeneity across studies; no randomized surveillance comparison. Equity: HPV+ OPC increasingly affects middle-aged men without traditional risk factors; racial disparities in access to surveillance programs. Evidence Maturity (confirmed): Validated. Original triage_score: 8
Article 13 — Cadoná et al. — Gastric fluid DNA: novel endoscopic liquid biopsy methodology (PMID: 42725339)
🔴 EARLY_CANCER_DETECTION | Proof-of-concept methodology study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel tumor-proximal liquid biopsy source; methodologically creative and potentially high-yield |
| Clinical Relevance | 4 | Proof-of-concept only; requires clinical validation before use |
| Population Reach | 8 | Gastric cancer is 5th most common cancer globally (~1M new cases/year); major early-detection gap |
| Implementation Speed | 2 | Requires endoscopic procedure + analytical protocol validation; years from clinical use |
| Evidence Strength | 3 | Methodology paper; no clinical performance data reported |
Key quantitative result: Feasibility demonstrated; no sensitivity/specificity data in abstract. External validation: None yet. Main limitation: Requires endoscopy (invasive); methodology paper without clinical outcomes data. Equity: Gastric cancer disproportionately affects East Asian, Latin American, and Eastern European populations; endoscopic access varies widely. Evidence Maturity (confirmed): Exploratory. Original triage_score: 8
Article 14 — Tang et al. — ctDNA clearance as trial-level surrogate endpoint (meta-analysis) (PMID: 42724868)
🔴 EARLY_CANCER_DETECTION | Meta-analysis (trial-level)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Trial-level surrogacy validation is methodologically important but builds on existing ctDNA clearance literature |
| Clinical Relevance | 7 | Could reshape drug approval timelines and trial design; indirect but high-value impact |
| Population Reach | 9 | Applies across solid tumors; impacts all cancer drug development |
| Implementation Speed | 5 | FDA/EMA acceptance of ctDNA clearance as surrogate endpoint requires regulatory engagement |
| Evidence Strength | 7 | Trial-level meta-analysis is appropriate methodology for surrogacy validation |
Key quantitative result: "Significant correlation to overall survival" — specific R² surrogate threshold not reported in abstract. External validation: Multi-trial synthesis. Main limitation: Surrogacy at trial level does not guarantee individual-level benefit; heterogeneity across cancer types may limit applicability. Equity: Validated surrogate could accelerate drug approval in cancers affecting underserved populations. Evidence Maturity (confirmed): Validated (for surrogate endpoint purpose). Original triage_score: 8
Article 15 — Bazan Russo et al. — cfDNA epigenetic profiling for early lung cancer detection (systematic review) (PMID: 42724581)
🔴 EARLY_CANCER_DETECTION | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Epigenetic cfDNA for lung cancer is an active field; this review synthesizes rather than advances |
| Clinical Relevance | 7 | Lung cancer is the leading cancer killer; improved early detection is high priority |
| Population Reach | 9 | Lung cancer: 2.2M new cases/year globally; high-risk populations enormous |
| Implementation Speed | 3 | Methodology still maturing; prospective validation trials needed |
| Evidence Strength | 5 | Systematic review of heterogeneous studies; no primary data |
Key quantitative result: Multiple methylation markers with higher sensitivity than CA125/mutation analysis — specific performance metrics not reported in abstract. External validation: Synthesizes existing literature. Main limitation: High heterogeneity across included studies; no head-to-head clinical comparison; publication bias. Equity: Lung cancer disproportionately affects low-income populations and heavy smokers; improved early detection has high equity potential. Evidence Maturity (confirmed): Exploratory. Original triage_score: 8
Article 16 — Baloescu et al. — AI enables non-experts to capture lung ultrasound B-lines (PMID: 42728197)
🟢 NEAR_TERM_IMPLEMENTABLE | Clinical validation study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI-guided ultrasound guidance for non-experts is an active area; this validates a specific implementation |
| Clinical Relevance | 8 | Point-of-care lung ultrasound has immediate application in emergency, primary care, and low-resource settings |
| Population Reach | 8 | Pulmonary edema and pneumonia are among the most common acute presentations globally |
| Implementation Speed | 6 | Technology requires device availability, training integration, and workflow adoption |
| Evidence Strength | 6 | Clinical validation study; specific performance metrics and comparator design not clear from abstract |
Key quantitative result: "Accuracy comparable to expert sonographers" — specific sensitivity/specificity not reported. External validation: Multi-site validation inferred from author list breadth. Main limitation: Abstract only; unclear if head-to-head with expert is randomized or parallel; clinical outcomes (not just image quality) not assessed. Equity: High potential to democratize POCUS in resource-limited settings; but device cost and connectivity remain barriers. Evidence Maturity (confirmed): Validated (for image acquisition accuracy). Original triage_score: 8
Article 17 — Karakus et al. — SAFE microwave device for breast density assessment (PMID: 42728183)
🟢 NEAR_TERM_IMPLEMENTABLE | Prospective validation study (novel device)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Non-ionizing microwave breast density assessment is genuinely novel; radiation-free alternative |
| Clinical Relevance | 6 | Breast density assessment important but incremental improvement; MRI remains superior for dense breasts |
| Population Reach | 8 | Breast cancer screening affects hundreds of millions of women globally |
| Implementation Speed | 4 | Device regulatory approval needed; validation at early stage |
| Evidence Strength | 4 | Single-center prospective validation; novel device at early validation stage |
Key quantitative result: "Comparable to gold-standard mammography" — specific ICC/kappa not reported in abstract. External validation: None yet; single-center. Main limitation: Single-center; early validation; mammography is imperfect comparator for dense breasts specifically. Equity: Radiation-free device particularly valuable for women requiring frequent screening or in under-resourced settings. Evidence Maturity (confirmed): Exploratory. Original triage_score: 8
Article 18 — Griguolo et al. — Actionable genomic alterations in breast cancer brain metastases (PMID: 42727421)
🟠 NOVEL_TREATMENT | Molecular profiling study (cohort)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Genomic profiling of BCBM is established; higher actionability rate vs. primary tumors is a useful quantification |
| Clinical Relevance | 8 | Directly supports tissue re-biopsy at CNS progression; actionable for oncologists today |
| Population Reach | 5 | ~15–30% of metastatic breast cancer patients develop brain metastases; sizable subgroup |
| Implementation Speed | 6 | Biopsy + NGS at CNS progression is technically feasible now; requires practice change |
| Evidence Strength | 6 | Cohort study; multi-institutional inferred; no comparator arm; abstract only |
Key quantitative result: Actionable alterations "substantially higher" in BCBM vs. primary — specific percentages not reported in abstract. External validation: Multi-center cohort adds validity. Main limitation: Not randomized; biopsy feasibility in all CNS lesions is not universal; actionable ≠ treatable with available CNS-penetrant agents. Equity: BCBM disproportionately affects HER2+ and TNBC patients (who have higher brain met rates), including younger patients and Black women. Evidence Maturity (confirmed): Validated. Original triage_score: 8
Article 19 — Fang et al. — Serum HE4 and long-term mortality in US women (NHANES) (PMID: 42727538)
⬜ STANDARD | Nationally representative cross-sectional study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | HE4 as a gynecologic oncology marker is established; mortality association in general population is a new angle |
| Clinical Relevance | 5 | Provocative but cross-sectional; no causal link established; not yet actionable |
| Population Reach | 8 | Nationally representative female population; potential for broad screening application |
| Implementation Speed | 4 | Requires prospective validation and clinical utility demonstration before implementation |
| Evidence Strength | 6 | NHANES methodology is rigorous; cross-sectional design limits causality |
Key quantitative result: HE4 independently associated with all-cause and cardiovascular mortality — HR not reported in abstract. External validation: NHANES is nationally representative; internally valid but external validation of mortality prediction not assessed. Main limitation: Cross-sectional; cannot exclude reverse causality; non-cancer HE4 elevation mechanisms unclear. Equity: NHANES nationally representative; findings relevant across racial/ethnic groups in US. Evidence Maturity (confirmed): Validated (for association); clinical utility exploratory. Original triage_score: 8
Article 20 — De Luca et al. — 21-center cohort + external validation of UICC staging for salivary gland carcinomas (n=892) (PMID: 42727269)
🟡 UNDERSERVED_POPULATION | Multicenter cohort with external validation
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Prognostic staging validation is methodologically sound; not a new discovery |
| Clinical Relevance | 7 | Fills critical evidence gap for rare cancer with limited prior data; immediately applicable |
| Population Reach | 2 | Rare cancer (~5,000/year US); high relative impact within affected population |
| Implementation Speed | 7 | Validated staging model can be adopted immediately into oncology practice |
| Evidence Strength | 8 | n=892, 21 centers, external validation — exceptionally rigorous for a rare cancer study |
Key quantitative result: Independent prognostic factors and staging validation — specific HRs not reported in abstract. External validation: Explicit external validation performed — methodological strength. Main limitation: Retrospective; rare cancer heterogeneity; treatment era effects across centers. Equity: Rare cancers chronically underserved in guideline development; this fills a meaningful gap. Evidence Maturity (confirmed): Validated. Original triage_score: 8
Article 21 — Groot et al. — Pancreatic ductal adenocarcinoma: clinical trials to watch (review) (PMID: 42727566)
🟠 NOVEL_TREATMENT | Clinical review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Landscape review; synthesizes existing/planned trials rather than generating new evidence |
| Clinical Relevance | 7 | PDAC is deadliest major cancer; framing of emerging precision strategies is clinically relevant |
| Population Reach | 7 | ~60,000 new PDAC cases/year US; nearly universal lethality |
| Implementation Speed | 2 | Trials are entering or in early phase; 5–10 years to practice change |
| Evidence Strength | 3 | Expert review; no primary data |
Key quantitative result: N/A (review). External validation: N/A. Main limitation: Review article; no primary data; pipeline trials may fail. Equity: PDAC disproportionately affects Black Americans; precision approaches require genomic infrastructure unavailable in many settings. Evidence Maturity (confirmed): Exploratory. Original triage_score: 8
Article 22 — Cai et al. — ADCs in ICI-refractory hepatocellular carcinoma (systematic review) (PMID: 42727892)
🟠 NOVEL_TREATMENT | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ADCs in HCC are an emerging but increasingly populated space; synthesis useful |
| Clinical Relevance | 7 | ICI-refractory HCC is a large and growing unmet need with very poor prognosis |
| Population Reach | 7 | HCC ~900,000 new cases/year globally; ICI is now first-line; post-ICI is large population |
| Implementation Speed | 3 | ADCs in HCC are in early trials; approval years away |
| Evidence Strength | 4 | Systematic review of early-phase trial data; limited primary evidence quality |
Key quantitative result: "Meaningful antitumor activity" — specific ORR/OS data not reported in abstract. External validation: Synthesizes multiple early-phase studies. Main limitation: Early-phase trial data only; limited comparator evidence; HCC molecular heterogeneity complicates ADC target selection. Equity: HCC most prevalent in sub-Saharan Africa and East/Southeast Asia; access to ADCs in high-burden regions is minimal. Evidence Maturity (confirmed): Exploratory. Original triage_score: 8
Article 23 — Utley Lyons et al. — Peripheral blasts at apheresis as risk factor for tisagenlecleucel outcomes in pediatric B-ALL (PMID: 42727020)
🟠 NOVEL_TREATMENT | Retrospective cohort study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Blast count as a CAR-T predictor is biologically intuitive; this study quantifies and validates it |
| Clinical Relevance | 8 | Directly modifiable pre-treatment factor; can change apheresis timing and bridging intensity today |
| Population Reach | 3 | Pediatric relapsed/refractory B-ALL is rare but devastating; high relative need |
| Implementation Speed | 7 | Retrospective finding actionable now for centers performing pediatric CAR-T |
| Evidence Strength | 6 | Retrospective multi-center cohort; no randomized blast-reduction intervention |
Key quantitative result: Peripheral blasts independently predict inferior survival — specific HR/threshold not reported in abstract. External validation: Multi-center retrospective dataset adds some validity. Main limitation: Retrospective; optimal blast count threshold unclear; product manufacturing variability confounds. Equity: Pediatric CAR-T available only at specialized centers; access disparities are profound. Evidence Maturity (confirmed): Validated (for risk stratification). Original triage_score: 8
Article 24 — Chen et al. — Antibody therapeutics in EGFR-mutant NSCLC (narrative review) (PMID: 42727894)
🟠 NOVEL_TREATMENT | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Amivantamab and ADCs in EGFR NSCLC are already known; review synthesizes rather than discovers |
| Clinical Relevance | 7 | Post-osimertinib resistance is a real clinical problem; therapeutic landscape overview useful |
| Population Reach | 8 | EGFR-mutated NSCLC is a major global cancer subtype |
| Implementation Speed | 4 | Some agents (amivantamab) approved; others in trials |
| Evidence Strength | 3 | Narrative review; no primary data; subject to selection bias |
Key quantitative result: N/A (review). External validation: N/A. Main limitation: Narrative review; incomplete evidence synthesis; no meta-analytic rigor. Equity: EGFR NSCLC enriched in Asian, never-smoker, and female populations; access to amivantamab + subsequent agents varies globally. Evidence Maturity (confirmed): Exploratory. Original triage_score: 8
Article 25 — My Tran et al. — Non-pharmacological interventions for T2DM metabolic control (meta-analysis) (PMID: 42727859)
🟢 NEAR_TERM_IMPLEMENTABLE | Systematic review and meta-analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Well-established evidence base; meta-analysis adds statistical pooling but no conceptual novelty |
| Clinical Relevance | 8 | Lifestyle intervention is first-line T2DM; high-quality pooled evidence reinforces and quantifies effect |
| Population Reach | 10 | ~537M adults with diabetes globally; lifestyle interventions applicable worldwide |
| Implementation Speed | 7 | Findings immediately applicable; no regulatory or cost barriers |
| Evidence Strength | 7 | Meta-analysis of RCTs; robust methodology |
Key quantitative result: Significant improvements in HbA1c, lipids, BP, and body composition — specific effect sizes not reported in abstract. External validation: Pooled across multiple RCTs. Main limitation: Heterogeneity in intervention types; sustainability of lifestyle changes in real-world settings; intervention dose not standardized. Equity: Non-pharmacological interventions are lower-cost and potentially more accessible in LMIC; structured programs still require resources. Evidence Maturity (confirmed): Potentially Practice-Changing (reinforcement of established practice with pooled quantification). Original triage_score: 8
Article 26 — Moran et al. — Composite tool for predicting gestational diabetes/hypertensive disorders of pregnancy (PMID: 42727299)
🟢 NEAR_TERM_IMPLEMENTABLE | Prediction model development and validation
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | GDM prediction models exist; composite cardiometabolic tool combining both GDM and HDP is modestly novel |
| Clinical Relevance | 7 | Early identification of at-risk pregnancies is clinically actionable; interventions exist |
| Population Reach | 8 | GDM affects ~14% of pregnancies globally; HDP ~5–10%; enormous global population |
| Implementation Speed | 5 | Model validation complete; EHR integration and clinical workflow adoption needed |
| Evidence Strength | 6 | Development + temporal validation performed; external geographic validation not described |
Key quantitative result: "Clinically actionable performance characteristics" — specific AUC/sensitivity not reported in abstract. External validation: Temporal validation performed; geographic validation not described. Main limitation: Single development cohort; temporal validation alone insufficient for generalizability; interventions post-prediction not studied. Equity: GDM disproportionately affects South Asian, Black, and Hispanic women; accessible prediction tool could reduce disparities if deployed equitably. Evidence Maturity (confirmed): Validated (prediction performance). Original triage_score: 8
Article 27 — Villalba et al. — Mutational landscape and clonal dynamics in AML undergoing PTCy HCT (n=191) (PMID: 42727885)
⬜ STANDARD | Retrospective cohort with targeted NGS
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | NGS profiling in AML at transplant is established practice; PTCy-specific context adds some novelty |
| Clinical Relevance | 6 | Useful for pre-transplant risk stratification; actionability depends on available interventions |
| Population Reach | 4 | AML patients eligible for myeloablative allo-HCT with PTCy is a defined subpopulation |
| Implementation Speed | 5 | NGS is available at transplant centers; findings applicable now |
| Evidence Strength | 6 | n=191 retrospective; targeted NGS; no randomized intervention |
Key quantitative result: Mutational profiles influence outcomes — specific HR per mutation not reported in abstract. External validation: Single-center (inferred); retrospective. Main limitation: Retrospective; single-center likely; PTCy-specific context may limit broader applicability. Equity: AML outcomes differ by race/ethnicity; PTCy availability varies globally. Evidence Maturity (confirmed): Validated (descriptive). Original triage_score: 7
Article 28 — Quintero et al. — Latin American consensus for PTCL-NOS diagnosis/staging/treatment (PMID: 42727046)
🟡 UNDERSERVED_POPULATION | Expert consensus statement
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Consensus for underrepresented region; adapts existing evidence rather than generating new science |
| Clinical Relevance | 8 | Directly fills a critical guidance gap for clinicians in Latin America managing an aggressive lymphoma |
| Population Reach | 3 | PTCL-NOS is rare (~5% of lymphomas); but Latin America represents a large underserved population |
| Implementation Speed | 8 | Consensus guidance immediately adoptable by regional oncologists |
| Evidence Strength | 4 | Expert consensus; inherits quality of underlying evidence which is limited for PTCL-NOS |
Key quantitative result: N/A (consensus). External validation: Multi-institutional; large author group adds geographic breadth. Main limitation: Limited underlying RCT evidence; consensus may reflect expert opinion more than data. Equity: Addresses a major equity gap in oncology guideline development for Latin American populations. Evidence Maturity (confirmed): Validated (consensus methodology). Original triage_score: 7
Article 29 — Gentile et al. — Marine microplastic pollution and cancer incidence in US coastal counties (PMID: 42727556)
⬜ STANDARD | Ecological cohort study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Environmental microplastics-cancer link at population level is genuinely novel and provocative |
| Clinical Relevance | 3 | Ecological design; causal inference impossible; no actionable clinical intervention |
| Population Reach | 8 | US coastal populations (~130M) plus global implications |
| Implementation Speed | 1 | Policy, not clinical; requires further mechanistic and prospective evidence |
| Evidence Strength | 3 | Ecological study; subject to ecological fallacy; many confounders |
Key quantitative result: Positive association between microplastic pollution and cancer incidence — specific RR not reported in abstract. External validation: None; single ecological study. Main limitation: Ecological fallacy; numerous confounders; no individual-level exposure data; correlation ≠ causation. Equity: Coastal communities with highest microplastic exposure often lower-income and minority communities. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 30 — Österlund et al. — UMI family size optimization for ctDNA in childhood cancers (PMID: 42727690)
⬜ STANDARD | Analytical/methodological study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | UMI optimization is a technical advance; important for field but niche |
| Clinical Relevance | 4 | Methodological improvement; clinical outcomes not measured |
| Population Reach | 3 | Pediatric cancer with ctDNA monitoring; specialized application |
| Implementation Speed | 4 | Applicable to labs running tumor-informed ctDNA assays |
| Evidence Strength | 5 | Methodological study; analytical rigor assessed |
Key quantitative result: UMI family size significantly impacts sensitivity/specificity — specific thresholds not reported in abstract. External validation: Not described. Main limitation: Methods paper; no clinical outcome validation. Equity: Pediatric ctDNA monitoring access varies significantly by institution. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 31 — Jhuang et al. — Long-read discovery of cis-spliced fusion RNA panel in cancer cell lines (PMID: 42727325)
⬜ STANDARD | Discovery + clinical validation study | classification_confidence: medium
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Long-read sequencing of cis-spliced fusion RNAs is technically novel; previously invisible targets |
| Clinical Relevance | 3 | Cell line discovery; clinical validation nascent |
| Population Reach | 5 | Potential broad cancer application via TCGA validation |
| Implementation Speed | 2 | Technology and analytical pipeline require significant development for clinical use |
| Evidence Strength | 3 | Cell line based; medium classification confidence; limited clinical translation |
Scores conservatively reduced per classification_confidence = medium rule.
Key quantitative result: Fusion RNA panel with prognostic significance — specific details not reported in abstract. External validation: TCGA correlation performed. Main limitation: Cell line discovery; TCGA validation is observational; medium classification confidence. Equity: N/A at this stage. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 32 — Leow et al. — DNA methylation biomarkers for early ovarian cancer detection (systematic review) (PMID: 42726150)
🔴 EARLY_CANCER_DETECTION | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | cfDNA methylation for ovarian cancer detection is a growing field; review synthesizes existing evidence |
| Clinical Relevance | 7 | Ovarian cancer detected late in ~75% of cases; better early detection is critically needed |
| Population Reach | 6 | ~314,000 new ovarian cancer cases/year globally; all women are at general risk |
| Implementation Speed | 3 | Biomarkers still in discovery/validation; clinical implementation years away |
| Evidence Strength | 4 | Systematic review; underlying studies likely small and heterogeneous |
Key quantitative result: Several methylation loci outperform CA125 in early-stage disease — specific sensitivity/specificity not reported in abstract. External validation: Synthesizes literature; no independent validation. Main limitation: Small, heterogeneous underlying studies; publication bias; loci not yet validated prospectively. Equity: Ovarian cancer disproportionately affects BRCA1/2 carriers; LMIC early-detection programs minimal. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 33 — Jump Salcedo et al. — Evolving landscape of paediatric sepsis (narrative review) (PMID: 42727989)
⬜ STANDARD | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | AI for sepsis is established; pediatric-specific framing adds value but not groundbreaking |
| Clinical Relevance | 6 | Sepsis is a leading pediatric killer; AI early warning systems could have high impact |
| Population Reach | 8 | Pediatric sepsis kills ~3M children/year globally |
| Implementation Speed | 3 | Narrative review identifying gaps; validated tools not yet presented |
| Evidence Strength | 2 | Narrative review; no primary data; no systematic methodology |
Key quantitative result: N/A (review). External validation: N/A. Main limitation: Narrative format; no systematic search; no primary evidence. Equity: Pediatric sepsis disproportionately affects LMIC children; AI tools validated in high-income settings may not transfer. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 34 — Liuzzi et al. — Near-nerve electrostimulation for consciousness assessment in pDoC (PMID: 42727595)
⬜ STANDARD | Clinical observational study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Near-nerve electrostimulation revealing hidden consciousness is a novel approach beyond standard CRS-R |
| Clinical Relevance | 6 | Profound implications for individual patients; reclassification could change care pathway |
| Population Reach | 3 | pDoC patients are a small but critically underserved population |
| Implementation Speed | 4 | Method needs multi-site validation before adoption |
| Evidence Strength | 4 | Observational; small sample likely; no randomized design |
Key quantitative result: Electrostimulation reveals residual consciousness where CRS-R is negative — specific N and proportion not reported. External validation: None described. Main limitation: Small, single-center likely; observational; behavioral CRS-R vs. neurophysiological responses may not be commensurable. Equity: DoC patients are profoundly vulnerable; misclassification of consciousness has profound ethical and care implications. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 35 — Saibaba et al. — AI for brain cancer management: multimodal digital workflows (systematic review) (PMID: 42727528)
⬜ STANDARD | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multimodal AI in GBM is an active field; systematic synthesis useful but not novel |
| Clinical Relevance | 5 | GBM is universally fatal; better diagnostics/planning could improve outcomes; validation gap limits relevance |
| Population Reach | 4 | GBM ~14,000/year US; rare but devastating |
| Implementation Speed | 3 | Prospective clinical validation and interoperability remain critical unresolved gaps |
| Evidence Strength | 4 | Systematic review of heterogeneous AI studies; high risk of overoptimism |
Key quantitative result: Multimodal AI outperforms single-modality — specific AUC not reported in abstract. External validation: Synthesizes existing literature. Main limitation: Retrospective AI studies; no prospective clinical trial data; generalizability across institutions limited. Equity: GBM patients in LMIC lack access to advanced imaging and AI systems. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 36 — Wang et al. — Post-RPL depression/anxiety impact on live birth rates and cardiometabolic risk (cohort) (PMID: 42727502)
🟡 UNDERSERVED_POPULATION | Retrospective cohort (national population-based)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Mental health after pregnancy loss affecting subsequent outcomes is known; cardiometabolic link is novel component |
| Clinical Relevance | 7 | Directly supports integrating mental health screening into RPL care pathways; clinically modifiable factor |
| Population Reach | 7 | RPL affects ~1–5% of reproductive-age women; depression/anxiety post-loss is common |
| Implementation Speed | 5 | Screening integration feasible; treatment pathways exist but implementation requires system change |
| Evidence Strength | 5 | Retrospective national cohort; selection and ascertainment biases possible |
Key quantitative result: Untreated depression/anxiety significantly reduces live birth rates — specific RR not reported in abstract. External validation: National population-based cohort adds scale. Main limitation: Retrospective; depression/anxiety ascertainment likely ICD-based; treatment vs. untreated not randomized. Equity: Mental health screening access in RPL care highly variable; particularly underserved in LMIC. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 37 — Liu et al. — Melanoma burden in elderly East Asians 1990–2023 with ML projection to 2040 (PMID: 42727032)
⬜ STANDARD | GBD-based epidemiological analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Melanoma epidemiology in East Asia is understudied; trend analysis + ML projection adds value |
| Clinical Relevance | 5 | Informs health policy and screening program design; not directly practice-changing at individual level |
| Population Reach | 8 | East Asia has 1.6B+ population; elderly demographic growing rapidly |
| Implementation Speed | 3 | Policy change; requires program development |
| Evidence Strength | 6 | GBD data robust; ML projection adds uncertainty but method is transparent |
Key quantitative result: Substantial increase in melanoma burden 1990–2023; accelerating projections to 2040 — specific incidence rates not reported in abstract. External validation: GBD dataset is widely used and peer-reviewed. Main limitation: GBD data quality varies by country; ML projections extrapolate from trends. Equity: Melanoma in East Asian populations historically underestimated; acral lentiginous melanoma is more common and harder to detect. Evidence Maturity (confirmed): Validated (epidemiological trend). Original triage_score: 7
Article 38 — Webber et al. — Spaced retrieval practice improves neuropsychological feedback uptake (RCT) (PMID: 42726908)
⬜ STANDARD | Randomized controlled trial
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Spaced retrieval practice is established in education; application to neuropsychological feedback is the novelty |
| Clinical Relevance | 5 | Improves cognitive health information uptake; downstream clinical outcomes not measured |
| Population Reach | 6 | Neuropsychological assessment is common in aging populations; scalable approach |
| Implementation Speed | 7 | Low-cost, immediately applicable modification to existing clinical practice |
| Evidence Strength | 6 | RCT; appropriate design; outcome is behavioral intention, not clinical outcome |
Key quantitative result: Significantly improved information retention and behavioral intention — effect sizes not reported in abstract. External validation: Not described. Main limitation: Outcome is cognitive retention/intention, not actual clinical behavior change or health outcome; limited generalizability beyond veteran sample. Equity: Study includes Black and White veterans — diverse sample; but veteran population limits generalizability. Evidence Maturity (confirmed): Validated (for behavioral intention outcome). Original triage_score: 7
Article 39 — Kramer et al. — Ex vivo bone marrow subniches and antibody-secreting cell fate (PMID: 42726849)
⚪ PROMISING_PRELIMINARY | Ex vivo experimental study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Spatially organized niche control of plasma cell longevity is a conceptually important finding with vaccine implications |
| Clinical Relevance | 3 | Basic science; vaccine durability implications are indirect and long-term |
| Population Reach | 7 | Vaccine durability in aging adults is a universal public health issue |
| Implementation Speed | 2 | Ex vivo model; clinical application 10+ years away |
| Evidence Strength | 5 | Human ex vivo tissue model; compelling but not in vivo validated |
Key quantitative result: Niche spatial signals govern plasma cell survival duration — specific quantitative outcomes not reported in abstract. External validation: None yet. Main limitation: Ex vivo model; in vivo and clinical validation needed; mechanistic complexity of bone marrow niche limits translation. Equity: Vaccine durability gaps disproportionately affect immunocompromised and elderly populations in LMIC. Evidence Maturity (confirmed): Exploratory. Original triage_score: 7
Article 40 — Migliaccio et al. — Thymidine kinase 1 activity as prognostic biomarker in HR+ metastatic breast cancer (systematic review) (PMID: 42727162)
⬜ STANDARD | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TKa as a biomarker in breast cancer has prior evidence; this review synthesizes |
| Clinical Relevance | 5 | Useful for monitoring but no evidence it changes treatment decisions; additive to existing tools |
| Population Reach | 7 | HR+ MBC is the most common metastatic breast cancer subtype |
| Implementation Speed | 4 | TKa assay not widely available; would need standardization |
| Evidence Strength | 4 | Systematic review of likely heterogeneous and small studies |
Key quantitative result: Consistent association with progression — specific pooled HR not reported in abstract. External validation: Synthesizes literature. Main limitation: Underlying studies likely small/heterogeneous; TKa assay standardization lacking; no evidence of treatment decision impact. Equity: HR+ MBC affects all demographic groups; biomarker access varies. Evidence Maturity (confirmed): Exploratory. Original triage_score: 6
Article 41 — Xu et al. — Ferroptosis regulation in cancer drug resistance (systematic review) (PMID: 42727656)
⬜ STANDARD | Systematic review | Mixed species (in vitro + human)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Ferroptosis in cancer is a growing field; epigenetic regulation angle is relatively novel |
| Clinical Relevance | 3 | Pre-clinical; no approved ferroptosis modulators yet |
| Population Reach | 7 | Drug resistance is universal across cancer types |
| Implementation Speed | 2 | Early mechanistic discovery; years from clinical application |
| Evidence Strength | 3 | Primarily in vitro evidence; mixed species |
Clinical Relevance capped at 5 per non-human/mixed species data; independent judgment: 3 reflects actual pre-clinical only status.
Key quantitative result: N/A (review of mechanisms). External validation: N/A. Main limitation: In vitro evidence base; no clinical translation demonstrated; medium classification confidence. Equity: Drug resistance is universal; ferroptosis pathway may offer LMIC-compatible intervention if drugs are simple. Evidence Maturity (confirmed): Exploratory. Original triage_score: 6
Article 42 — DeCoster & Narla — GLP-1 receptor agonists for dermatologic comorbidities (narrative review) (PMID: 42727867)
⬜ STANDARD | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GLP-1 anti-inflammatory effects in skin are an emerging area; narrative review synthesizes |
| Clinical Relevance | 5 | Psoriasis and HS have major unmet need; GLP-1 off-label use is growing but evidence sparse |
| Population Reach | 7 | Psoriasis affects ~125M globally; GLP-1 RA prescribed to millions |
| Implementation Speed | 4 | Off-label use possible now but lacks RCT evidence; prescribers cautious |
| Evidence Strength | 3 | Narrative review; no primary data; selective literature coverage |
Key quantitative result: N/A (narrative review). External validation: N/A. Main limitation: Narrative; no systematic search; mechanism-to-benefit extrapolation without RCT data. Equity: GLP-1 RA cost remains prohibitive for many; dermatological benefits may be accessible if already prescribed for metabolic indications. Evidence Maturity (confirmed): Exploratory. Original triage_score: 6
Article 43 — Cao et al. — Population PK/PD modeling of NH600001 in elderly anesthesia patients (PMID: 42728212)
⬜ STANDARD | Population PK/PD modeling | Unsolicited find
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | PK/PD modeling for age-specific dosing is standard pharmaceutical science; NH600001 is novel agent |
| Clinical Relevance | 5 | Geriatric anesthesia safety is important; novel agent needs dosing data |
| Population Reach | 7 | Elderly surgical patients are a very large population globally |
| Implementation Speed | 3 | NH600001 not yet approved; clinical trials needed |
| Evidence Strength | 5 | PK/PD modeling is appropriate methodology; model predictions require clinical confirmation |
Key quantitative result: Significant age-related PK differences requiring dose adjustment — specific PK parameters not reported in abstract. External validation: Model validation described but not externally confirmed clinically. Main limitation: Modeling study; clinical outcomes not assessed; agent not yet approved. Equity: Elderly surgical patients in LMIC often receive outdated anesthetic agents; novel safer alternatives have equity implications. Evidence Maturity (confirmed): Exploratory. Original triage_score: 6
Article 44 — Vural Doğru et al. — Acupressure for back pain/fatigue after coronary angiography (RCT) (PMID: 42728195)
🟢 NEAR_TERM_IMPLEMENTABLE | RCT | Unsolicited find
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Acupressure for procedural discomfort is not new; specific application post-angiography is modestly novel |
| Clinical Relevance | 5 | Reduces procedural discomfort; limited impact on major clinical outcomes |
| Population Reach | 7 | Millions of coronary angiographies performed annually globally |
| Implementation Speed | 8 | Nurse-delivered; no cost/regulatory barrier; immediately implementable |
| Evidence Strength | 6 | RCT with sham control; appropriate design; single-blind (not double-blind) limitation |
Key quantitative result: Significant reduction in back pain and fatigue vs. standard care — specific VAS scores not reported in abstract. External validation: Not described; single-center likely. Main limitation: Single-blind; subjective outcomes; single-center; limited generalizability. Equity: Low-cost intervention; applicable in LMIC catheterization labs. Evidence Maturity (confirmed): Validated (for procedural comfort outcomes). Original triage_score: 6
Article 45 — Majeed et al. — Pulmonary complications in AML post-allo-HSCT: BAL and biopsy diagnostic yield (PMID: 42728133)
⬜ STANDARD | Retrospective cohort study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Well-recognized complication; single-center retrospective data adds limited new knowledge |
| Clinical Relevance | 5 | Useful for transplant center protocols but not practice-changing |
| Population Reach | 4 | AML post-allo-HSCT subpopulation; specialized |
| Implementation Speed | 5 | Retrospective findings immediately applicable to protocol design |
| Evidence Strength | 4 | Single-center retrospective; subject to selection bias |
Key quantitative result: Pulmonary complications in 40–60% of patients; high mortality — specific BAL diagnostic yield not reported in abstract. External validation: None; single-center. Main limitation: Single-center retrospective; small sample likely; no standardized diagnostic algorithm assessed. Equity: Allo-HSCT access is highly unequal globally. Evidence Maturity (confirmed): Validated (descriptive epidemiology). Original triage_score: 5
Article 46 — Wang et al. — Predictive model for refractory Mycoplasma pneumoniae pneumonia in children (CBC-based) (PMID: 42724116)
⬜ STANDARD | Development and validation study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CBC-based predictive models for pneumonia severity are established; Mycoplasma-specific is modestly novel |
| Clinical Relevance | 5 | Early identification of high-risk pediatric pneumonia has direct management implications |
| Population Reach | 6 | Mycoplasma pneumoniae pneumonia is the most common atypical pneumonia in children globally |
| Implementation Speed | 5 | CBC is universally available; model could be implemented in any pediatric center |
| Evidence Strength | 5 | Development + validation performed; temporal validation not described; single-center likely |
Key quantitative result: "Accurately identifies children at risk" — specific AUC not reported in abstract. External validation: Internal validation described; external validation not confirmed. Main limitation: Single-center likely; external validation not described; abstract only. Equity: CBC-based model is accessible in LMIC settings; high relevance for global pediatric care. Evidence Maturity (confirmed): Exploratory. Original triage_score: 5
Article 47 — Vassallo et al. — MGAT1 as druggable target in STK11-mutant NSCLC (CRISPR screen) (PMID: 42727848)
⚪ PROMISING_PRELIMINARY | Genome-wide CRISPR screen | In vitro
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel glycosyltransferase target via CRISPR screen in ICI-resistant NSCLC; genuinely new mechanism |
| Clinical Relevance | 2 | In vitro only; no human data; no drug yet |
| Population Reach | 6 | STK11-mutant NSCLC is ~15–20% of NSCLC; large subgroup with current unmet need |
| Implementation Speed | 1 | Target identification stage; drug development 10+ years |
| Evidence Strength | 4 | CRISPR screen + biochemical validation; in vitro only; no animal data reported |
Clinical Relevance capped at 5 per non-human study rule; independent score: 2 reflects genuine pre-clinical stage.
Key quantitative result: MGAT1 identified as synthetic lethal in STK11-mutant context — specific effect sizes not reported in abstract. External validation: Biochemical validation performed; no in vivo validation described. Main limitation: In vitro only; target validation in animal models and human tumors needed. Equity: STK11 mutations enriched in smokers and certain ethnic populations. Evidence Maturity (confirmed): Exploratory. Original triage_score: 5
Article 48 — Vogt et al. — Novel pipeline for manganese chelator validation in Mn-transporter disorders (in vitro/ex vivo) (PMID: 42727654)
⚪ PROMISING_PRELIMINARY | In vitro/ex vivo pipeline validation | In vitro
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | iPSC + zebrafish pipeline for ultra-rare juvenile Parkinsonism is genuinely innovative |
| Clinical Relevance | 3 | In vitro/ex vivo; no human treatment data yet |
| Population Reach | 2 | Ultra-rare; <100 known cases of Mn-transporter disorders globally |
| Implementation Speed | 2 | Drug candidates identified; clinical trials needed; years away |
| Evidence Strength | 4 | In vitro + ex vivo validation; no human data |
Population Reach scored relative to ultra-rare disease unmet need: high relative score within affected community; absolute population is tiny.
Key quantitative result: Chelator candidates prioritized — specific efficacy data not reported in abstract. External validation: Pipeline validated across two model systems. Main limitation: Pre-clinical; no patient treatment data; ultra-rare disease limits trial feasibility. Equity: Rare disease with no approved treatment; equity is about access to the pipeline itself — needs global rare disease infrastructure. Evidence Maturity (confirmed): Exploratory. Original triage_score: 5
Article 49 — Khalifa et al. — Monocarboxylate transporter 1 deficiency: case report and systematic review (PMID: 42724849)
🟡 UNDERSERVED_POPULATION | Case report with systematic review | classification_confidence: medium
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Characterization of known ultra-rare disorder; adds to case literature |
| Clinical Relevance | 4 | Diagnostic clarity for affected families; no treatment advance |
| Population Reach | 1 | Extremely rare; <50 confirmed cases in literature |
| Implementation Speed | 4 | Genetic framework immediately useful for counseling |
| Evidence Strength | 3 | Case report + systematic review of reported cases; medium classification confidence |
Scores conservatively reduced per classification_confidence = medium rule.
Key quantitative result: Genetic spectrum of SLC16A1 pathogenic variants characterized — specific variant count not reported in abstract. External validation: Systematic review aggregates case reports; no independent validation possible. Main limitation: Case reports only in underlying literature; small numbers; medium confidence classification. Equity: Ultra-rare disease; genetic counseling access is rare globally. Evidence Maturity (confirmed): Exploratory. Original triage_score: 4